Who is sponsoring NCT03649126?

NCT03649126 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT03649126?

Interventions in NCT03649126: Implementation tools.

What condition does NCT03649126 study?

NCT03649126 studies Standardized Structured Reporting.

Is NCT03649126 still recruiting?

NCT03649126 is currently status unknown. Last updated 28 August 2018.

Last reviewed 2018-08-28 · How we verify

NCT03649126: IMPROVING

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nationwide Implementation of Standardized Structured Reporting

Status unknown Last updated 28 August 2018

What this trial tests

trial testing Implementation tools in Standardized Structured Reporting in 50 participants. Status unknown.

Timeline

21 August 2018

Primary endpoint
30 June 2020

30 June 2020

Quick facts

Lead sponsor	Radboud University Medical Center
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	21 August 2018
Primary completion	30 June 2020
Estimated completion	30 June 2020
Sites	1 location across Netherlands

Drugs / interventions tested

Implementation tools

Conditions studied

Standardized Structured Reporting — all drugs for Standardized Structured Reporting →

Sponsor

Radboud University Medical Center

Who can join

Adults 18 to 68, any sex, with Standardized Structured Reporting. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The first objective is to explore factors that impede or facilitate implementation of SSR in pathology (and other disciplines) among the MDT members receiving SSRs. The second objective is to select, develop and evaluate (process and effect outcomes) implementation tools supporting optimal implementation of SSR in pathology. The third objective is to offer implementation tools to all pathology laboratories in the Netherlands and to share the SSR-kit for successful implementation with other medical disciplines

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03649126 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 28 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03649126.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing